The results of the phase 3 CAPItello-281 study showed that Truqap (capivasertib) improved radiographic progression-free ...

The report from techUK welcomes the new Labour government's recognition that "decisive change" – underpinned by digital ...

Rumours that Donald Trump had chosen Martin Makary as FDA Commissioner have been confirmed, while the President-elect has ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with ...

DXPs can now eliminate swivel chair processes. Commercial organisations can integrate existing systems with a DXP and have ...

The genomic medicine space has seen incredible success, but investors are overlooking it. For once, it’s not efficacy that’s ...

The company made its debut last year with a $51 million Series A and a licensing agreement with Astellas for a gene therapy ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...

Mendelsohn – using history as a guide – suggests there will be a layering of new laws, with, for example, a push for changes ...

Donald Trump has chosen talk show host and celebrity doctor Dr Mehmet Oz to lead the Centers for Medicare and Medicaid ...